Advertisement

News

Make CHEST Physician® a trusted source
  • AI applications in pulmonary medicine: From training clinicians to transforming diagnostics and treatment

    AI applications in pulmonary medicine: From training clinicians to transforming diagnostics and treatment

    AI applications in health care are multiplying, and AI-focused research is gaining traction across specialties, including pulmonary, critical care, and sleep medicine.


  • Data show OSA is an independent, modifiable risk factor for cerebral microbleeds

    Data show OSA is an independent, modifiable risk factor for cerebral microbleeds

    The first prospective, longitudinal study of OSA and cerebral microbleeds (CMBs) found that moderate to severe OSA more than doubles the risk for microbleeds.


  • Targeting capillary refill time identified as superior resuscitation strategy

    Targeting capillary refill time identified as superior resuscitation strategy

    Yuri Matusov, MD, said recent findings mark a significant step toward an individualized approach for managing septic shock.



  • Trials suggest RSV vaccine reduces hospitalization for cardiorespiratory conditions in older adults

    Trials suggest RSV vaccine reduces hospitalization for cardiorespiratory conditions in older adults

    Data from studies in the United States and Denmark add to the growing evidence that respiratory syncytial virus (RSV) vaccination is effective in older adults.


  • Third trial supports sotatercept to treat PAH

    Third trial supports sotatercept to treat PAH

    Guidelines expert James R. Klinger, MD, FCCP, said that while the evidence of efficacy is clear, more research is needed to address questions regarding the optimal duration of therapy and the potential for disease progression if therapy is stopped.


  • Study demonstrates strong patient compliance with oral device for OSA

    Study demonstrates strong patient compliance with oral device for OSA

    Evidence suggests that an oral device may be an effective alternative for patients who can’t access or tolerate CPAP therapy.


  • The climate cost of inhalers: What prescribers should know

    The climate cost of inhalers: What prescribers should know

    Experts said clinicians must ensure patients have the therapies they need at affordable prices that, ideally, impose minimal amounts of environmental harm.


  • Phase 3 IMPALA-2 clinical trial shows inhaled molgramostim promising for autoimmune pulmonary alveolar proteinosis

    Phase 3 IMPALA-2 clinical trial shows inhaled molgramostim promising for autoimmune pulmonary alveolar proteinosis

    An ongoing 96-week, open-label period of the trial is designed to shed light on the drug’s long-term safety and efficacy.



  • Oseltamivir found to lower risk of flu-linked neuropsychiatric events in children

    Oseltamivir found to lower risk of flu-linked neuropsychiatric events in children

    This study is the largest and most comprehensive US investigation of the drug and severe neuropsychiatric events, said author James Antoon, MD, PhD, MPH.


  • Data suggest pneumococcal vaccination is underused

    Data suggest pneumococcal vaccination is underused

    Respiratory medicine expert Christina Thornton, MD, PhD, said recent real-world data demonstrate high rates of community-acquired pneumonia driven by serotypes targeted by vaccines.